Corium to Present Positive Data on ADHD Medication AZSTARYS® & Alzheimer's Disease Medication ADLARITY® at Psych Congress 2022

ReachMD Healthcare Image

09/14/2022

Photo: Pixabay

Finance.Yahoo.com

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announces the debut of positive data on September 18, 2022, at the upcoming Psych Congress 2022 in New Orleans about its two FDA-approved  medicines, AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) for patients six and older with ADHD, and ADLARITY (donepezil transdermal system) for patients with mild, moderate, or severe dementia of the Alzheimer's type.

The five poster presentations affirm Corium's progress in developing transformative medicines that improve the health of patients with CNS disorders. Among the three posters reporting new AZSTARYS findings are the debut of analysis of the medicine's effects on children's sleep, disorder severity reduction, and real-world usage. The two ADLARITY posters will report bioequivalence and safety comparisons with oral donepezil and new skin tolerability results of the transdermal formulation.

"The positive data from Corium that will be featured at Psych Congress 2022 deliver meaningful knowledge about our two CNS treatments, AZSTARYS for ADHD and ADLARITY for dementia due to Alzheimer's disease," said Charles Oh, M.D., Chief Medical Officer of Corium. "Our broad participation at Psych Congress is also a significant milestone highlighting Corium's ongoing commitment and leadership in the CNS therapeutic space."

Corium's Psych Congress 2022 posters will be presented on Sunday, September 18, and Monday, September 19, from 1:30 to 3:00 pm CDT (2:30 to 4:00 pm EDT) in Hall D of the New Orleans Convention Center.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free